Overview
- Novo Nordisk announced that Wegovy tablets will be introduced in German pharmacies on Tuesday, September 1, and the company says it has enough supply to meet expected demand.
- The pills are prescription‑only and approved in the EU for adults with obesity or for adults with overweight plus at least one weight‑related comorbidity, so doctors must assess who qualifies.
- Oral Wegovy delivers the same active molecule as the injectable but requires daily fasting dosing and much higher oral amounts because the gut absorbs only a tiny fraction of the drug.
- Clinical trials show average weight losses of about 11–17 percent, yet a British study found that roughly 60 percent of lost weight was regained one year after stopping treatment, underscoring limits to long‑term benefit without ongoing therapy.
- Patients will likely pay out of pocket in Germany where weight‑loss drugs are treated as lifestyle medicines, which could drive high demand, affordability debates, and warnings from experts and pharmacists against unsupervised online purchases and use without medical follow‑up.